Amgen's Breakthrough in Cancer Treatment: Targeting KRAS Mutations

Amgen's scientists have developed the first approved medicine to directly target KRASG12C, a common driver of cancer. The breakthrough, recognized by the American Chemical Society's Heroes of Chemistry award, underscores the power of targeted therapies and purpose-driven science to benefit patients. The KRAS mutation plays a major role in helping tumors grow and survive, especially in lung, colon, and pancreatic cancers. Amgen's therapy has the potential to provide a new treatment option for patients with these types of cancer.